Summary
Egg quality is one of the most decisive yet least controllable factors in a woman’s fertility journey, and for millions of Indian women, it is also the least understood. Poor egg quality underlies a significant proportion of failed conceptions, miscarriages, and unsuccessful IVF cycles, yet it rarely receives the targeted nutritional support it deserves. Surishi Pharmaceuticals’ MITOV uses NMN, CoQ10 and EGCG to address egg-quality factors, including oxidative stress in follicular fluid, chromosomal integrity during meiosis, granulosa cell health, and the energy environment within maturing oocytes.
Introduction
Ask most women navigating fertility challenges what “egg quality” actually means biologically, and the answer is rarely clear. Fertility clinics assess it indirectly through embryo grading and IVF outcomes.
Yet women rarely receive the conversation about what actually determines whether an egg can be fertilised, divide correctly, and implant successfully, as well as what can be done to improve these outcomes in a form they can act on.
Egg quality is not a single measurement. It is the cumulative result of a complex biological environment: the health of the follicular fluid surrounding the developing oocyte, the integrity of the chromosomes being segregated during meiosis, the energy levels powering every step of maturation, and the degree of oxidative stress that the egg has been exposed to during its development.
Each of these factors is influenced by nutritional status, cellular health, and the presence or absence of the right biochemical support during the critical weeks before ovulation.
Drawing on scientific insights championed by Surishi Pharmaceuticals and supported by the expertise of the Surishi Academic Council, modern fertility solutions increasingly focus on optimising these underlying biological factors to improve reproductive outcomes.
This stage is where MITOV intervenes. Developed by Surishi Pharmaceuticals under the rigorous oversight of the Surishi Academic Council, MITOV is a multi-ingredient formulation designed to act on the specific cellular pathways that determine egg quality before the egg is ever released, fertilised, or evaluated by an embryologist.
It is a proactive, science-backed approach to reproductive health that begins not in the clinic but inside the cell.
How MITOV’s Ingredients Improve Egg Quality Step by Step
MITOV’s clinical value lies in the specificity with which each ingredient targets a distinct aspect of egg quality, creating a comprehensive protective and restorative environment for the developing oocyte.
1. NMN: Restoring the Energy Currency of Egg Maturation
The core active substance, NMN (β-nicotinamide mononucleotide), can restore NAD+ levels in oocytes; NAD+ is responsible for mitochondrial energy supply and DNA repair. A study published in Cell Reports shows that NMN supplementation can improve reproductive indicators and reduce oocyte fragmentation rates, and that NAD+ levels in follicular fluid are positively correlated with oocyte maturation and fertilisation rates.
2. CoQ10: Powering Chromosomal Segregation and Maturation
Coenzyme Q10’s role in oocyte quality far exceeds previous understandings: it not only supports the mitochondrial respiratory chain activity required for oocyte meiosis but also alleviates two major age-related reproductive challenges, namely ovarian aging and poor oocyte quality.
Multiple prior studies have also confirmed that coenzyme Q10 can increase the number of retrieved mature oocytes, fertilisation rates, and high-quality embryo rates, effectively improving the inherent quality of oocytes.
3. Astaxanthin: Protecting the Follicular Environment
As a potent antioxidant, astaxanthin, in application scenarios of assisted reproductive technology and in vitro fertilisation, can enhance the total antioxidant capacity of follicular fluid, optimise the microenvironment for oocyte maturation, reduce the oxidative load that damages oocyte DNA and disrupts chromosome alignment during meiosis, ultimately improving the initial quality of retrieved oocytes and bringing fertility benefits to women receiving treatment.
4. EGCG: Targeted Protection for Aged Oocytes
Epigallocatechin gallate (EGCG), extracted from green tea, is the core research object for oocyte quality studies in reproductive medicine. Studies published on the PMC platform have confirmed that, relying on its antioxidant activity, it can improve the quality of aged oocytes both in vivo and in vitro and alleviate infertility linked to oxidative stress.
Its anti-inflammatory properties further protect granulosa cells from the chronic low-grade inflammation that accompanies PCOS and endometriosis, as well as the oxidative environment of the ageing ovary, thereby preserving the follicular support structure that every maturing egg depends on.
The Reproductive Health Picture Beyond the Egg
Egg quality does not exist in isolation. The core dimensions of generalised reproductive health include hormone signalling, uterine receptivity, and full-cycle hormonal health, which regulate ovulation. MITOV can support this complete reproductive health system from a practically significant clinical level.
Astaxanthin, EGCG, and trans-resveratrol can exert their anti-inflammatory effects, reduce the overall systemic inflammatory load, and eliminate the adverse impacts of inflammation on ovulation and implantation.
The metabolic support provided by NMN and CoQ10 improves insulin sensitivity at the cellular level, directly relevant for women with PCOS, whose metabolic dysfunction creates an environment hostile to healthy egg development.
The sirtuin-activating properties of both Trans-Resveratrol and Trans-Pterostilbene support the epigenetic regulation of reproductive genes, helping to maintain the hormonal and cellular signalling that governs healthy ovarian function.
Together, these mechanisms position MITOV not merely as an egg quality supplement but as a comprehensive reproductive health formulation, one that works upstream of the problems that manifest as infertility, poor IVF outcomes, and hormonal irregularity.
Conclusion
PCOS and hormonal imbalance require a deeper understanding of metabolic, hormonal, and cellular health together. MITOV supports this approach by improving mitochondrial function and cellular energy balance, helping the body naturally regulate reproductive and hormonal systems through MITOV Surishi Pharmaceuticals and its science-driven wellness approach.
With innovative formulations like MITOV tablet India and a strong research foundation in Surishi Pharma products, Surishi Pharmaceuticals continues to strengthen its role in modern women’s healthcare.
The brand’s commitment to science, innovation, and reproductive health, Surishi Pharmaceuticals Delhi, guided by the Surishi Academic Council, reflects its long-term vision for women’s health across India.
FAQs
1. Can supplementation actually improve egg quality, or does age entirely determine it?
This study adopts oxidative stress, mitochondrial energy, and follicular antioxidant levels as its core variables. Building on previous research validating the restorative effects of NMN, CoQ10, and astaxanthin, this study proposes a combined supplementation intervention programme that is not age-restricted.
2. How is MITOV different from standard prenatal vitamins when it comes to egg quality?
Conventional prenatal vitamins, widely available on the market, can only provide support for gestation after conception. In contrast, the novel MITOV can regulate three categories of previously unaddressed core reproductive pathways before conception.
3. Is MITOV beneficial for women with endometriosis or poor follicular health?
The functional preparation MITOV contains EGCG and astaxanthin and is specifically developed for women with inflammatory diseases such as endometriosis. It can relieve pelvic inflammation, protect granulosa cells, and maintain follicle health.
4. When in the menstrual cycle should women focus on supporting egg quality?
Daily and consistently. Since follicular maturation takes approximately 85-90 days, the greatest improvement in egg quality is seen after 3 months of regular supplementation, not just in the days around ovulation.
(Message in Public Interest by Surishi Academic Council | Makers of MITOV)
